Use of β-lactam/β-lactamase inhibitor combinations to treat community-acquired respiratory tract infections

Infectious Diseases in Clinical Practice

Volumn 11, Issue SUPPL. 1, 2002, Pages

  Akalin, Erdal ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; PNEUMONIA; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0036079016     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-200202001-00004     Document Type: Review

References (25)

1. Management of adult community-acquired lower respiratory tract infections
2. Management of community-acquired pneumonia in the era of pneumococcal resistance
3. Practice guidelines for the management of community-acquired pneumonia
4. Canadian guidelines for the initial management of community acquired pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society
5. Antimicrobial susceptibility patterns of respiratory pathogens - A global perspective
6. Prognosis and outcomes of patients with community-acquired pneumonia
7. Study of community-acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines
8. A prediction rule to identify low-risk patients with community-acquired pneumonia
9. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae to oral antimicrobial agents
10. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
11. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis collected from five centers in Brazil, 1997-1998
12. β-lactamase production and the role of ampicillin/sulbactam
13. Sultamicillin (ampicillin-sulbactam) in the treatment of acute otitis media in children
14. Sultamicillin (sulbactam/ampicillin) versus amoxicillin in the treatment of acute otitis media in children
15. An open comparative study of the efficacy and safety of sultamicillin versus cefaclor in the treatment of acute otitis media in children
16. Clinical use of sultamicillin (ampicillin/sulbactam) in children
17. An open multicentre study to compare the efficacy and safety of sultamicillin with that of cefuroxime axetil in acute ear nose and throat infections in adults
18. Clinical evaluation of sultamicillin in lower respiratory tract infections
19. A comparison of ampicillin/sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalised patients
20. A noncomparative study of the safety and efficacy of parenteral sulbactam/ampicillin followed by oral sultamicillin for the treatment of lower respiratory tract infections
21. Switch therapy with β-lactam/β-lactamase inhibitors in patients with community-acquired pneumonia
22. Rationaler einstaz oraler antibiotika in der praxis
23. Guidelines for the role of antibiotics in acute exacerbations of chronic bronchitis in the Asia Pacific region: Report and recommendations of a consensus group
24. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
25. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease